Home Cart Sign in  
Chemical Structure| 4773-96-0 Chemical Structure| 4773-96-0

Structure of Mangiferin
CAS No.: 4773-96-0

Chemical Structure| 4773-96-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mangiferin is the predominant constituent of extracts of the mango plant Mangifera Indica L. with potential antidiabetic activity.

Synonyms: NSC 248870; Alpizarin; Aphloiol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mangiferin

CAS No. :4773-96-0
Formula : C19H18O11
M.W : 422.34
SMILES Code : O=C1C2=C(OC3=C1C=C(O)C(O)=C3)C=C(O)C([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2O
Synonyms :
NSC 248870; Alpizarin; Aphloiol
MDL No. :MFCD00075656
InChI Key :AEDDIBAIWPIIBD-ZJKJAXBQSA-N
Pubchem ID :5281647

Safety of Mangiferin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVECs) 10, 50 μM 72 hours To investigate the inhibitory effect of mangiferin on high glucose-induced endothelial-mesenchymal transition (EndMT). Results showed that mangiferin dose-dependently inhibited high glucose-induced EndMT, as evidenced by increased CD31 expression and decreased expression of mesenchymal markers such as α-SMA and vimentin. Acta Pharmacol Sin. 2024 May;45(5):1002-1018
Primary channel catfish hepatocytes 1.25 µM 12 hours Mangiferin significantly down-regulated the expression of sqle (p=0.030) and reduced cholesterol levels (p=0.000). Antioxidants (Basel). 2024 Jun 13;13(6):722
NCTC 1469 cells 1.25 µM 12 hours Mangiferin significantly down-regulated the expression of sqle (p=0.000) and reduced cholesterol levels (p=0.024). Antioxidants (Basel). 2024 Jun 13;13(6):722
MH7A cells 1.69 ng/ml 24 hours Inhibited LPS/ATP-induced pyroptosis, reduced TUNEL-positive cells Front Immunol. 2022 Jun 21;13:912933
RAW264.7 cells 1.69 ng/ml 24 hours Inhibited LPS/ATP-induced pyroptosis, reduced PI-positive cell rate Front Immunol. 2022 Jun 21;13:912933
mushroom tyrosinase 0–1000 µg/mL 15 minutes Mangiferin inhibited tyrosinase activity in a dose-dependent manner with an IC50 of 0.290 ± 0.006 mM. Antioxidants (Basel). 2023 Apr 28;12(5):1016

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Streptozotocin (STZ)-induced diabetic pulmonary fibrosis model Intragastric administration 20, 60 mg/kg Every 3 days for 4 weeks To investigate the protective effect of mangiferin on diabetic pulmonary fibrosis. Results showed that mangiferin dose-dependently alleviated diabetes-induced pulmonary fibrosis without affecting long-term blood glucose levels. Acta Pharmacol Sin. 2024 May;45(5):1002-1018
Channel catfish (Ictalurus punctatus) High-starch diet-induced hepatic injury and lipid accumulation model Dietary supplementation 100 mg/kg and 500 mg/kg Twice daily for eight weeks Mangiferin alleviated high-starch-induced hepatic damage and lipid accumulation by modulating cholesterol metabolism, significantly reducing plasma and liver cholesterol levels (p=0.000). Antioxidants (Basel). 2024 Jun 13;13(6):722
Lewis rats Adjuvant-induced arthritis-modified rat model Oral administration 600.912 mg/kg Once daily for 30 days Alleviated arthritis severity, inhibited TLR4/PI3K/AKT/NF-κB signaling, suppressed NLRP3 inflammasome activation and pyroptosis Front Immunol. 2022 Jun 21;13:912933

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.84mL

2.37mL

1.18mL

23.68mL

4.74mL

2.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories